Helicobacter pylori infects an estimated half of the world’s population and remains highly prevalent across the Eastern Mediterranean region. The bacterium colonizes the gastric mucosa, where it drives chronic inflammation and, in a subset of those infected, progresses to peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, or adenocarcinoma of the stomach. Eradicating the organism is therefore not merely a matter of relieving dyspepsia; it is a recognized cancer-prevention strategy. Yet the standard triple therapy that dominated H. pylori treatment for decades, a proton pump inhibitor combined with clarithromycin and amoxicillin, has been losing ground worldwide as clarithromycin resistance has climbed, and in Syria the decline has been compounded by antibiotic misuse, disrupted healthcare infrastructure, and limited access to diagnostic resources.

When clarithromycin-based regimens fail or cannot be relied upon, clinicians frequently turn to levofloxacin, a fluoroquinolone antibiotic, as the backbone of alternative combinations. Two such combinations were tested in this trial. The concomitant regimen delivers a proton pump inhibitor, levofloxacin, amoxicillin, and a fourth agent simultaneously for the full 14 days, so the patient takes all drugs at once throughout the treatment period. The sequential regimen splits the therapy into phases: one antibiotic pairing is given first, followed by a second pairing, with the theoretical rationale that an initial phase of amoxicillin reduces bacterial load and damages cell walls in a way that may improve the effectiveness of the subsequent phase while limiting the window in which resistance can emerge.

Sequential therapy has been promoted in some settings as a way to sidestep clarithromycin resistance, and it has been studied extensively in Europe and Asia, but it had never been formally evaluated in Syrian patients. The researchers, led by Marouf Alhalabi of Damascus Hospital together with colleagues at Ibn Al-Nafees Hospital and the Syrian Board in Gastroenterology, designed a single-center, prospective, open-label, randomized superiority trial to answer the question directly under local conditions. The trial was prospectively registered on ClinicalTrials.gov as NCT06065267 on October 3, 2023, and received ethics approval from the Damascus Hospital and Ibn Al-Nafees Ethics Committee under approval number 41/23.

The study enrolled 150 adults with histologically confirmed H. pylori infection, all of whom had never previously received eradication therapy. Participants were assigned equally, 75 to each arm, to either the concomitant or the sequential levofloxacin-based regimen, each lasting 14 days. The primary outcome was eradication success, confirmed by a negative stool antigen test performed six weeks after the completion of therapy, a timing chosen to allow residual bacterial antigen to clear and to avoid false-positive results. The analysis followed the intention-to-treat principle, meaning every randomized patient was counted in the group to which they were assigned regardless of whether they completed the full course, an approach that preserves the real-world validity of the comparison by accounting for dropouts and imperfect adherence.

The numbers told a story of near-equal performance. Concomitant therapy eradicated the infection in 63 of 75 patients, an intention-to-treat rate of 84 percent, while sequential therapy succeeded in 61 of 75, or 81.3 percent. The absolute risk difference was 2.7 percentage points, with a 95 percent confidence interval spanning from minus 9.4 to 14.8, and the comparison yielded a p value of 0.83 with an odds ratio of 1.20, corresponding to a confidence interval of 0.516 to 2.81. In plain terms, the data provide no evidence that one regimen outperforms the other, and the confidence interval is wide enough that a modest advantage in either direction cannot be excluded. The authors were careful to state that the absence of a statistically significant difference does not establish equivalence or non-inferiority, a distinction that matters in clinical trial interpretation: proving two treatments equal requires a trial designed and powered for that purpose, which this superiority trial was not.

Both regimens were generally well tolerated, an important consideration given that eradication therapy requires patients to take multiple medications daily for two weeks. Nausea was the most frequently reported adverse event in both groups, followed by anorexia, headache, a persistent bitter taste, and skin rash. There was no significant difference in the frequency of adverse events between the two arms, suggesting that the added complexity of the sequential schedule does not buy any tolerability advantage. Baseline characteristics of the two groups were comparable, reducing the likelihood that imbalances in age, sex, or disease profile skewed the outcome.

The findings arrive against a backdrop of genuine clinical constraint. In settings where culture and susceptibility testing are unavailable, clinicians must prescribe empirically, choosing regimens based on regional resistance data and local experience rather than on the resistance profile of an individual patient’s infection. Syria’s healthcare system has been strained by years of conflict and economic crisis, and the authors note that susceptibility-guided therapy and many of the internationally recommended first-line regimens may simply be unavailable. In that context, levofloxacin-based empirical therapy remains in use, and the question of which levofloxacin-based strategy to choose is not academic. The trial suggests that when such therapy is required, the simpler concomitant regimen may offer practical advantages: a single, uniform dosing schedule for 14 days is easier to explain, easier to follow, and less prone to the confusion that phased regimens can introduce, with no measurable cost in effectiveness.

The moderate eradication rates observed in both arms, in the low-to-mid 80 percent range, also serve as a reminder that levofloxacin resistance itself is a growing problem in many regions, and that no empirical regimen can be assumed to work indefinitely. The authors emphasize that these findings should be interpreted in light of local resistance patterns and healthcare limitations, and they call for further multi-center studies that incorporate antimicrobial susceptibility testing. Such studies would allow clinicians to match therapy to the actual resistance profile of circulating H. pylori strains, an approach that international guidelines increasingly favor but that remains aspirational in much of the Eastern Mediterranean.

For the broader field, the trial adds a data point from a population that is rarely represented in H. pylori treatment literature. Most eradication trials are conducted in East Asia, Europe, or North America, where resistance patterns, drug availability, and patient populations differ substantially from those in conflict-affected or resource-limited settings. Demonstrating that a straightforward four-drug concomitant regimen achieves roughly 84 percent eradication in treatment-naïve Syrian patients, and that a more complex sequential schedule offers nothing extra, gives local clinicians an evidence-based reason to favor simplicity. As antibiotic resistance continues to erode the effectiveness of legacy regimens worldwide, trials like this one, grounded in the realities of a specific healthcare environment rather than in idealized conditions, are becoming an essential complement to guideline committees’ recommendations.

Subject of Research: A randomized trial comparing levofloxacin-based concomitant and sequential therapies for Helicobacter pylori eradication in treatment-naïve Syrian patients.

Article Title: Levofloxacin-based concomitant versus sequential therapy for Helicobacter pylori eradication in treatment-naïve Syrian patients: a randomized trial showing no superiority of sequential therapy

Article References: Alhalabi, M., Alshiekh, H. A., Sheikh Alhara, A. A., Ismail, A. A., Shehab, W., & Osamah, W. (2026). Levofloxacin-based concomitant versus sequential therapy for Helicobacter pylori eradication in treatment-naïve Syrian patients: a randomized trial showing no superiority of sequential therapy. Gut Pathogens. https://doi.org/10.1186/s13099-026-00881-x

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00881-x

Keywords: Helicobacter pylori, levofloxacin, concomitant therapy, sequential therapy, eradication therapy, antibiotic resistance, randomized clinical trial, Syria, gastroenterology, stool antigen test, fluoroquinolone, clinical trial

Helicobacter pylori remains one of the most consequential human pathogens on the planet, colonizing the gastric mucosa of roughly half the world’s population and serving as the dominant risk factor for peptic ulcer disease, chronic gastritis, and gastric adenocarcinoma. Eradicating the bacterium has become progressively harder over the past two decades as clarithromycin and levofloxacin resistance has spread, pushing clinicians toward bismuth quadruple therapy and, more recently, toward dual therapies that pair a potent acid suppressant with high-dose amoxicillin. The logic of these dual regimens is elegant: by driving intragastric pH sharply upward, the acid blocker undermines H. pylori’s ecological niche and enhances amoxicillin’s stability and activity against actively dividing bacteria, while restricting the antibiotic arsenal to a single agent helps preserve susceptibility of other organisms. The arrival of vonoprazan, which binds reversibly to the gastric H+/K+-ATPase at a potassium-binding site and achieves faster, stronger, and more sustained acid inhibition than classical proton pump inhibitors, has energized this strategy, but direct comparisons with optimized proton pump inhibitor dual regimens have remained limited, particularly regarding collateral effects on the gut microbiome.

To address that gap, the research team enrolled a total of 110 H. pylori-positive patients and non-randomly assigned them to one of two fourteen-day-style dual regimens. Fifty patients received the P-CAB regimen, consisting of vonoprazan 20 milligrams twice daily combined with amoxicillin 750 milligrams four times daily, while sixty patients received the PPI regimen, comprising esomeprazole 20 milligrams four times daily with the same amoxicillin dosing. Twenty-two H. pylori-negative individuals served as healthy controls for microbiota benchmarking. Eradication success was determined four weeks after completion of therapy using the 13C-urea breath test, a noninvasive assay that exploits the bacterium’s urease enzyme to detect active infection. The investigators also gathered fecal samples at three time points, baseline before treatment, roughly two weeks into the post-therapy window, and at week six, to characterize shifts in microbial diversity, community composition, and predicted functional pathways through 16S rRNA gene sequencing.

On the pharmacological front, the two acid suppressants differ in ways that matter clinically. Proton pump inhibitors such as esomeprazole are acid-activated prodrugs that require an acidic environment to engage the pump irreversibly, meaning their effect accumulates over several doses and is blunted in the very hypersecretory or proton-pump-dense patients who most need acid control. Vonoprazan, by contrast, is active at neutral pH, accumulates in parietal cells, and exerts dose-dependent, reversible inhibition that reaches near-anacidic gastric conditions within hours and persists through once- or twice-daily dosing. That kinetic advantage is thought to explain why vonoprazan-based dual therapy performs well even in regions with high amoxicillin resistance, since sustained acid suppression amplifies amoxicillin’s bactericidal window. The esomeprazole arm in this study used a four-times-daily schedule specifically to maximize acid suppression and keep the comparison fair against the twice-daily vonoprazan regimen.

The headline efficacy finding favored vonoprazan across every analysis population. The P-CAB group achieved an eradication rate of 97.73 percent in the per-protocol analysis, compared with 84.20 percent in the esomeprazole group, a difference that reached statistical significance at P equals 0.04. Although the intention-to-treat and modified intention-to-treat analyses showed the same directional advantage for the vonoprazan regimen, those comparisons did not cross the threshold of statistical significance, a nuance the authors attribute in part to the non-randomized design and the modest sample size. Still, a cure rate approaching 98 percent in patients who completed the prescribed course places the vonoprazan dual approach among the most effective antibiotic-sparing strategies reported, comfortably exceeding the 90 percent benchmark that international consensus guidelines set for first-line eradication therapy.

Equally important for practice, the safety and tolerability picture was essentially identical between arms. Adverse reactions, which in dual amoxicillin regimens typically include diarrhea, nausea, taste disturbances, rash, and abdominal discomfort, occurred at comparable frequencies in the two groups, and patient compliance did not differ significantly between the P-CAB and PPI regimens. Neither regimen caused treatment-related events severe enough to disrupt the comparison, suggesting that the pharmacological intensity of vonoprazan did not translate into a clinical tolerability penalty. For gastroenterologists weighing first-line options, this aligns the choice more squarely on efficacy grounds, since the operational burden of four-times-daily amoxicillin dosing applies to both regimens equally.

The microbiota component of the study adds a layer of ecological context that eradication trials rarely capture. Using 16S rRNA gene amplicon sequencing of the V3 and V4 hypervariable regions, the team quantified alpha diversity, assessed community structure with principal co-ordinates analysis, and predicted functional shifts against the Kyoto Encyclopedia of Genes and Genomes reference pathways. Both eradication regimens delivered a discernible shock to the gut ecosystem: microbial diversity declined after treatment, community composition shifted measurably away from baseline and from the healthy control profile, and predicted metabolic pathways were transiently perturbed. Importantly, these disturbances followed a recovery trajectory over the follow-up period, with communities migrating back toward their pretreatment configuration by week six.

The two regimens left subtly different ecological fingerprints. The early decline in microbial diversity was more pronounced in the vonoprazan group, an observation consistent with the deeper and more sustained acid suppression that P-CABs deliver, since gastric acid and its downstream influence on the entire intestinal milieu shape which microbes survive transit into the lower gut. Yet the vonoprazan group also showed a tendency toward faster restoration of functional pathway profiles, hinting that the compositional damage and the functional damage may recover on different clocks. Across both arms, the researchers documented an increase in potential pathogenic bacteria and a corresponding decrease in short-chain fatty acid-producing bacteria after treatment, a pattern that matters because short-chain fatty acids such as butyrate fuel colonocytes, maintain epithelial barrier integrity, and exert anti-inflammatory signaling throughout the body. The fact that these SCFA producers rebounded over the six-week window will reassure clinicians, though the study’s design cannot exclude longer-lasting effects in some individuals.

The authors caution, appropriately, that the study was non-randomized, single-center, and modest in size, so the eradication difference should be interpreted as hypothesis-confirming rather than definitive, and the microbiota findings describe short-term dynamics only. Even so, the report lands at a moment when clinicians worldwide are retooling first-line H. pylori strategies amid rising antibiotic resistance. Vonoprazan-based dual therapy is already endorsed by growing bodies of guideline literature as a first-line option, and this comparison provides practical reassurance on two fronts simultaneously: it beats an optimized esomeprazole dual regimen where it counts, achieving eradication close to the theoretical ceiling while matching that regimen on safety and adherence, and the collateral microbiota damage it inflicts appears to be transient and self-repairing. For a bacterium that infects billions and drives one of the world’s most common cancers, treatment strategies that maximize cure rates while minimizing ecological and resistance costs represent exactly the kind of progress the field has been seeking, and this study offers a candid, quantified look at both sides of that bargain.

Subject of Research: Comparative efficacy of vonoprazan-based versus esomeprazole-based dual therapy for Helicobacter pylori eradication and short-term gut microbiota changes

Article Title: Comparative effects of vonoprazan-based and esomeprazole-based dual therapy on Helicobacter pylori eradication and short-term gut microbiota changes

Article References: Liu, Y., Qian, X., Yao, J., Fei, C., Zhang, Z., & Jiang, Z. (2026). Comparative effects of vonoprazan-based and esomeprazole-based dual therapy on Helicobacter pylori eradication and short-term gut microbiota changes. Gut Pathogens. https://doi.org/10.1186/s13099-026-00867-9

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00867-9

Keywords: Helicobacter pylori, vonoprazan, esomeprazole, dual therapy, eradication, gut microbiota, 16S rRNA sequencing, potassium-competitive acid blocker, proton pump inhibitor, short-chain fatty acids, amoxicillin, 13C-urea breath test

The international team of researchers, led by Professor Mingxin Zhang and collaborators from Xi’an Medical University and its affiliated hospital, undertook a systematic review and meta-analysis encompassing 30 rigorous scientific studies. These included 16 randomized controlled trials (RCTs) and 14 prospective cohort studies—all carefully selected through exhaustive searches across major databases including PubMed, Embase, Web of Science, and the Cochrane Library, covering literature up to December 2024. This comprehensive approach allowed a robust synthesis of data evaluating the incidence or recurrence of reflux oesophagitis following H. pylori eradication therapy.

In their meticulous data analysis using Review Manager 5.4 software, the researchers identified a 39% increased risk of developing or experiencing recurrence of RE in patients undergoing H. pylori eradication therapy compared to placebo groups, as demonstrated by pooled data from the RCTs. This result, importantly, exhibited low heterogeneity (I²=28%), underscoring its statistical robustness and generalizability. Contrastingly, the cohort studies’ findings were less definitive, with high heterogeneity (I²=78%) and without achieving statistical significance, thereby suggesting intricate confounding influences in real-world observational data.

Delving deeper into age stratifications, the meta-analysis revealed no statistically significant increase in RE risk across different age categories—including younger adults (≤40 years), middle-aged individuals (40–60 years), and seniors (≥60 years). Nonetheless, a non-significant yet consistent trend of elevated relative risk in middle-aged groups was notable across study designs, hinting at potential age-related biological and environmental interactions modulating the post-eradication trajectory of the gastroesophageal mucosa.

Crucially, the presence of pre-existing gastrointestinal illnesses appeared to modulate risk profiles. In particular, patients diagnosed with peptic ulcer disease (PUD) exhibited a markedly higher RE risk post-eradication in randomized trials, a finding not mirrored in cohort studies. Conversely, no significant alterations in RE occurrence were observed among those with gastroesophageal reflux disease (GERD) or dyspepsia, although some prospective cohorts indicated an increase in dyspeptic patients. These nuanced differences underscore the complex pathophysiological interplay between H. pylori infection, mucosal integrity, and acid-related disorders.

Geographic analyses further illuminated intriguing variations in RE susceptibility following eradication therapy. While RCT data suggested elevated but statistically non-significant risks across Asia, the Americas, and Europe, cohort studies sharply delineated a significant risk elevation particularly within Asian populations, an observation absent in European cohorts. These findings emphasize the potential influence of region-specific factors such as genetic predispositions, dietary habits, microbiome compositions, and environmental exposures on disease progression and therapeutic response.

One of the more illuminating aspects of the study pertained to the temporal dynamics of RE risk. Longer follow-up durations exceeding one year consistently correlated with a significant increase in RE incidence, reinforcing a time-dependent deterioration of esophageal mucosal defenses or compensatory physiological changes after the clearance of H. pylori. This temporal association suggests that short-term assessments may underestimate the long-term gastroesophageal risks associated with eradication therapies.

From a mechanistic standpoint, this research invites a re-examination of H. pylori’s dualistic role within the upper gastrointestinal tract. Traditionally vilified as a pathogenic bacterium necessitating elimination, H. pylori may also exert protective effects against acid reflux by modulating gastric acid secretion and influencing gastric physiology. Its eradication likely disrupts this delicate balance, culminating in increased acid exposure, esophageal mucosal inflammation, and thus heightened RE risk, particularly in susceptible individuals.

The clinical ramifications of these findings are profound and multi-faceted. While H. pylori eradication indisputably remains vital for gastric cancer and ulcer prevention, a blanket ‘treat-all’ approach must now be tempered by an appreciation of potential downstream complications such as reflux oesophagitis. Physicians are urged to adopt a more personalized therapeutic strategy—carefully evaluating individual patient profiles, including age, baseline gastrointestinal health, and regional epidemiology—before initiating eradication protocols.

Moreover, diligent post-therapy monitoring emerges as a crucial component of patient management. Individuals undergoing treatment should be closely observed for reflux symptoms, facilitating early intervention and mitigating the risk of chronic esophagitis or its sequelae. This may encompass lifestyle modifications, pharmacologic acid suppression, or tailored follow-up endoscopies to preserve esophageal health.

Nevertheless, the authors candidly acknowledge the study’s limitations. The significant heterogeneity in cohort studies points to the complexities of observational research, including diverse patient populations, varied study designs, and potential confounders. Language restrictions to English and Chinese publications, as well as omission of unpublished data, may introduce selection bias. Furthermore, inconsistent reporting across studies hindered assessments of RE severity and precise temporal onset post-eradication. Lastly, reliance on infection status at final follow-up instead of initial eradication regimens may have induced some misclassification bias.

Despite these constraints, the meta-analysis’s rigor and the convergence of evidence from well-designed RCTs amplify the validity of its conclusions. This integrative work charts new territory in gastroenterological research, underscoring the multifaceted consequences of microbial manipulation within human hosts—especially in the tightly regulated milieu of the gastrointestinal tract.

In summation, this pivotal meta-analysis compellingly elucidates that while H. pylori eradication therapy remains a cornerstone of gastrointestinal disease prevention, it paradoxically may increase the risk of reflux oesophagitis, particularly with extended follow-up periods. These risks are nuanced, influenced by regional, demographic, and clinical variables, necessitating a more individualized and judicious approach to H. pylori treatment algorithms. Ultimately, this study highlights an urgent need for both enhanced awareness and further research into balancing microbial eradication benefits against potential gastrointestinal sequelae.

By decoding the intricate interplay between microbial infection, eradication strategies, and esophageal pathology, the findings pave the way for improved clinical guidelines and patient outcomes. As the global medical community continues to grapple with evolving understandings of the human microbiome’s role in health and disease, such comprehensive analyses serve as vital touchstones in shaping nuanced, patient-centric care paradigms.

Subject of Research: Association between Helicobacter pylori eradication and risk of reflux oesophagitis occurrence or recurrence.

Article Title: Association between infection of Helicobacter pylori and the risk of reflux oesophagitis occurrence or recurrence: a systematic review and meta-analysis.

News Publication Date: 2025.

Web References:

• DOI link: http://dx.doi.org/10.1136/egastro-2024-100121
• eGastroenterology Journal: egastroenterology.bmj.com

References: Li A, Zhang Y, Chen K, et al. Association between infection of Helicobacter pylori and the risk of reflux oesophagitis occurrence or recurrence: a systematic review and meta-analysis. eGastroenterology 2025;3:e100121.

Image Credits: Anna Li, Yanan Zhang, Kunping Chen, et al.

Keywords: Helicobacter pylori, reflux oesophagitis, eradication therapy, meta-analysis, randomized controlled trials, prospective cohort studies, gastroesophageal reflux disease, peptic ulcer disease, gastric cancer prevention, gastrointestinal microbiota, acid reflux, esophageal mucosa, regional variations.